Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.
Interdisciplinary Tinnitus Center of the University of Regensburg, Regensburg, Germany.
Sci Rep. 2019 Aug 22;9(1):12274. doi: 10.1038/s41598-019-48686-0.
Several studies emphasized the potential of single and multiple transcranial random noise stimulation (tRNS) sessions to interfere with auditory cortical activity and to reduce tinnitus loudness. It was the objective of the present study to evaluate the use of high-frequency (hf) tRNS in a one-arm pilot study in patients with chronic tinnitus. Therefore, 30 patients received 10 sessions of high frequency tRNS (100-640 Hz; 2 mA; 20 minutes) over the bilateral temporal cortex. All patients had received rTMS treatment for their tinnitus at least 3 months before tRNS. Primary outcome was treatment response (tinnitus questionnaire reduction of ≥5 points). The trial was registered at clinicaltrials.gov (NCT01965028). Eight patients (27%) responded to tRNS. Exactly the same number of patients had responded before to rTMS, but there were only two "double responders" for both treatments. None of the secondary outcomes (tinnitus numeric rating scales, depressivity, and quality of life) was significant when results were corrected for multiple comparisons. tRNS treatment was accompanied by tolerable side effects but resulted in temporal increases in tinnitus loudness in 20% of the cases (2 drop-outs). Our trial showed that hf-tRNS is feasible for daily treatment in chronic tinnitus. However, summarizing low treatment response, increase of tinnitus loudness in 20% of patients and missing of any significant secondary outcome, the use of hf-tRNS as a general treatment for chronic tinnitus cannot be recommended at this stage. Differences in treatment responders between tRNS and rTMS highlight the need for individualized treatment procedures.
几项研究强调了单次和多次经颅随机噪声刺激 (tRNS) 对干扰听觉皮层活动和降低耳鸣响度的潜在作用。本研究的目的是评估高频 (hf) tRNS 在慢性耳鸣患者单臂试验中的应用。因此,30 名患者接受了 10 次高频 tRNS(100-640 Hz;2 mA;20 分钟)治疗,双侧颞叶皮质。所有患者在接受 tRNS 治疗前至少接受了 3 个月的 rTMS 治疗。主要结局是治疗反应(耳鸣问卷评分降低≥5 分)。该试验在 clinicaltrials.gov 上注册(NCT01965028)。8 名患者(27%)对 tRNS 有反应。完全相同数量的患者在 rTMS 之前对 rTMS 有反应,但只有两个患者对两种治疗均有“双重反应”。当对多次比较进行校正时,次要结局(耳鸣数字评定量表、抑郁和生活质量)均无显著差异。tRNS 治疗伴有可耐受的副作用,但在 20%的病例中导致耳鸣响度暂时增加(2 例退出)。我们的试验表明,hf-tRNS 适用于慢性耳鸣的日常治疗。然而,由于治疗反应低、20%的患者耳鸣响度增加以及缺乏任何显著的次要结局,在现阶段,不能推荐使用 hf-tRNS 作为慢性耳鸣的一般治疗方法。tRNS 和 rTMS 之间治疗反应者的差异突出了个体化治疗方案的必要性。